Many authors demonstrated that the increase in absolute EGFR GCN detected by FISH, both in NSCLC and in mCRC [9,13], is associated with an improved response to TKI as gefitinib or to cetuximab or panitumumab respectively. Here, EGFR is linked to non-small cell lung carcinoma.